Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug

Dicerna, based in Lexington, Massachusetts, is having a massive week, with two major announcements. Today, the U.S. Food and Drug Administration (FDA) accepted Dicerna Pharmaceuticals and Eli Lilly and Company’s Investigational New Drug (IND) application for LY3819469. They will initiate a Phase I trial of the drug in cardiometabolic diseases.